TY - JOUR T1 - Engineered bacteria recruit and orchestrate anti-tumor immunity JF - bioRxiv DO - 10.1101/2022.06.16.496462 SP - 2022.06.16.496462 AU - Thomas M. Savage AU - Rosa L. Vincent AU - Sarah S. Rae AU - Lei Haley Huang AU - Alexander Ahn AU - Kelly Pu AU - Fangda Li AU - Courtney Coker AU - Tal Danino AU - Nicholas Arpaia Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/06/17/2022.06.16.496462.abstract N2 - Tumors employ multiple mechanisms to actively exclude or suppress adaptive immune cells involved in anti-tumor immunity. Strategies focused on overcoming these immunosuppressive or exclusion signals – through localized delivery of chemokines that directly recruit immune cells into the tumor microenvironment – remain limited due to an inability to target therapeutics specifically to the tumor. Synthetic biology enables engineering of cells and microbes for tumor localized delivery, offering therapeutic candidates previously unavailable using conventional systemic administration techniques. Here, we engineer bacteria to produce and intratumorally release chemokines to attract adaptive immune cells into the tumor environment. Intravenous or intratumoral delivery of bacteria expressing an activating mutant of the human chemokine CXCL16 (hCXCL16K42A) leads to the recruitment of activated T cells within tumors and offers therapeutic benefit in multiple mouse tumor models. Furthermore, we rationally target an additional step in the immune activation cascade – specifically, the presentation of tumor-derived antigens by dendritic cells – using a second engineered bacterial strain expressing CCL20. This combined targeting approach led to the recruitment of type 1 conventional dendritic cells and effectively synergized with hCXCL16K42A-induced T cell recruitment to provide additional therapeutic benefit. In summary, we engineer bacteria to cooperatively recruit and activate both innate and adaptive anti-tumor immune responses, offering a new cancer immunotherapy strategy.Competing Interest StatementT.M.S., R.L.V., T.D. and N.A. are inventors on a patent application describing the use of chemokine-expressing engineered bacteria for cancer immunotherapy (International Application No. PCT/US2022/016775). N.A. and T.D. have a financial interest in GenCirq, Inc. ER -